Name: Nasser Khodai Booran
E–mail: email@example.com & firstname.lastname@example.org
1.PhD in medical Biosciences/Biotechnology from Pasteur Institute of Iran and Collaborator Institutions 1996 ( All transcripts evaluated by WES in US and Canada)
2.MSc in medical microbiology 1991,
3.BSc in microbiology 1985.
4.Post doctoral in genetically engineered HIV vaccine in Pasteur Institute of PARIS-France 1996. Prof. Maurice Hofnung and Prof. Jean Marie Clement.
5.Visiting scientist, Prof. Cliff. L. Lingwood, 2003-2005
6.Researcher in Infectious Disease, Prof. Upton Allen’s EBV lab 2005-present.
7.miniMBA program, GMCA-Sickkids Hospital
Appointments/Work Experience Extensive practical and theoretical experiences in academic and industrial field (1980-2003) including medical microbiology/virology and biochemistry, genetic engineering, immunology, biotechnology and biological productions and clinical research.
1.1980-1987 Technician in private medical laboratories.
2.1987-1991 Technologist in Quality control of injectable solutions, microb-chem lab.
3.1992 Lecturer and Head of Microbiology Lab.
4.1992-94 Established first time molecular genetics lab and PCR diagnostics in for detection of HCMV, HSV, Toxoplasma etc.) Pasteur Institute of Iran.
5.1993-94Supervised and trained researcher and technologist for establish molecular genetics methods PCR, RFLP, etc. Ahwas Welfare Organization, Iran.
6.1994. Leading a team for production of biochemical diagnostic Kits and reagent.
7.1994-98 Head of Biochemistry Dept. and Principal and co-investigator in many projects Pasteur Institute of Iran.
8.1995-96 production of Hepatitis B Vaccine in Industrial complex. Pasteur Institute.
9.1996-2003Assistant/Associate Prof. Pasteur Institute of Iran.
10. 1998-2003 director of Public and international affairs, Pasteur Institute of Iran.
11. 2003-2005 Visiting professor at The hospital for Sick Children, Toronto, Canada
12.2005-Present Researcher at The hospital for Sick Children, Toronto, Canada
Training and courses:
2017: GMCA-Sickkids mimiMBA Program
2016: National Molecular Microbiology Diagnostic Users Group Annual Fall Meeting (NMG) Nov, 28, Sickkids hospital-Toronto
2016: The Genetic and Genomic Biology Program Annual Retreat- Sickkids hospital-Toronto
2016: OIRM, STEM CELL AND REGENERATIVE MEDICINE SYMPOSIUM, April 18 Sickkids hospital-Toronto
2016: Droplet Digital PCR-BIO-RAD workshop, April 13-14, TCAG, Sickkids hospital-Toronto
2016: RNA-seq Data Analysis Boot Camp by Centre for computational Medicine at Sickkids.
2015: a.Clinical research certificate b.Research program Judge c. UHPLC workshop,
2015: Department of Peadiatriv Research Day, May 27
2014: a. leadership workshop in manage conflict b. Research risk management c. research judge,
2013: DNA and /RNA Sequencing and Genotype Analysis Workshop
2008: Partek RNA and DNA Data Analysis Workshop- Sickkids hospital-Toronto.
2006: Real-Time PCR training course. Sickkids hospital-Toronto
2001: Second International Course on Infections and Cancer, WHO. Annecy, France
1995: Radiation Protection in Medicine, Atomic Energy Centre of Iran
1994: PCR and its applications. by Prof. F Kashanchi of NIH, USA
1993: Restriction Enzyme Purification by Prof. Rechenskii.
1992: Immunology and Molecular Biology of Infectious Diseases, ELIZA, western blot etc. by WHO.
1992: Animal Tissue Culture by W.H.O
1992 Selected visiting scientist and delegate from ministry of health to GlaxoSmithKline. Belgium.
1991-1992 Purification of immunoglobulins, Pasteur Institute
1991 Bacterial Genetic by Professor G.B. Smirnov-Pasteur Institute
1988: Medical parasitology courses (practical and theoretical)
Doctoral Thesis: Detection of human Herpes Viruses by Polymerase Chain Reaction (PCR) and its role in Pathophysiology of Atherosclerosis 1996 (PhD thesis).
1. The genetic diversity of Epstein-Barr virus in the setting of transplantation relative to non-transplant settings: A feasibility study. Pediatric Transplant. 2015 Nov 18. Allen D, Khodai-Booran N et al.
2. Prevalence of 30-bp deletion variant of latent membrane protein-1 in pediatric transplant patients compared with patients with infectious mononucleosis. Pediatric Transplantation. Allen D, Khodai-Booran N et al.
3. Correlates of illness severity in infectious mononucleosis. Can J Infect Dis Med Microbiol. 2014 Sep;25(5):277-80. Allen D, Khodai-Booran N et al.
4. An A-B Subunit Chimera of the E.Coli Verotoxin1 Provides a Receptor Probe and Potential Vaccine Approach. International Journal of Applied Biology and Pharmaceutical Technology Volume: 3: Issue-4: Oct-Dec -2012, Khodai-Booran N et al.
5. An A-B Subunit Chimera of the E.Coli Verotoxin1 Provides a Receptor Probe and Potential Vaccine Approach .The 31st Annual Meeting of the European Society for Pediatric Infectious Diseases, May 28-June01, 2013; Milan, Italy.
6. N. Khodai-Booran, and C. A. Lingwood et al. An A-B Subunit Chimera of the E.Coli Verotoxin1 Provides a Receptor Probe and Potential Vaccine Approach .The 31st Annual Meeting of the European Society for Paediatric Infectious Diseases,May28-June01,2013;Milan,Italy.
7. Upton Allen, Nasser Khodai-Booran et al. Genetic Diversity of Epstein - Barr virus in the Setting of Transplant Relative to Non-Transplant Settings: Proof-of-Principle.
AMMI Canada - CACMID Annual Conference
VICTORIA, BC April 3 – 5, 2014.
8. Odame J, Khodai-Booran N and Allen UD. Correlates of illness severity in infectious mononucleosis.
Can J Infect Dis Med Microbiol. 2014 Sep; 25(5):277-80.
9. U. Allen and N. Khodai-Booran et al. PREVALENCE OF 30-BP DELETION VARIANT OF LATENT MEMBRANE PROTEIN-1 IN PEDIATRIC TRANSPLANT PATIENTS COMPARED WITH PATIENTS WITH INFECTIOUS MONONUCLEOSIS. 8th International Congress of the International Pediatric Transplant Association (IPTA). March 28 – 31, 2015, at the Westin St., San Francisco, California.
10. U. Allen, N. Khodai-Booran et al. Division of Infectious Diseases1, The Transplant and Regenerative Medicine Centre2 and The Research Institute3, Hospital for Sick Children, University of Toronto
The genetic diversity of Epstein-Barr virus in the setting of transplantation relative to non-transplant settings: A feasibility study. 2016 Feb;20(1):124-9.
11. Genetic Diversity of Epstein - Barr Virus Lytic Gene BZLF-1 among Patients with and without Post-transplant Lymphoproliferative Disorder
Upton Allen, MD, FIDSA1,2, Marianna Abdulnoor, BSc (Candidate)1, Nasser Khodai-Booran, PhD1, Tara Paton, PhD3 et al. Hospital for Sick Children, Toronto, ON, Canada, (3)Research Institute, Hospital for Sick Children, Toronto, ON, Canada. ID Week 2017TM, October 4-8, 2017 at the San Diego Convention Center, in San Diego, CA.
Languages: English, French, Turkish (Azeri), Persian